{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T19:25:30Z","timestamp":1793215530391,"version":"4.5.0"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,5,26]],"date-time":"2025-05-26T00:00:00Z","timestamp":1748217600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,5,26]],"date-time":"2025-05-26T00:00:00Z","timestamp":1748217600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Zhejiang Health Science and Technology Project","award":["2021KY1034"],"award-info":[{"award-number":["2021KY1034"]}]},{"name":"the Project of NINGBO Leading Medical & Health Discipline","award":["2022-F05"],"award-info":[{"award-number":["2022-F05"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Pharmacol Toxicol"],"DOI":"10.1186\/s40360-025-00940-0","type":"journal-article","created":{"date-parts":[[2025,5,26]],"date-time":"2025-05-26T17:17:43Z","timestamp":1748279863000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Safety evaluation of baloxavir marboxil: analysis and discussion utilizing real adverse events from the FAERS database"],"prefix":"10.1186","volume":"26","author":[{"given":"Xiaolong","family":"Lai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liuyin","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yixia","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lindan","family":"Sheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guomin","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianjiang","family":"Fang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,5,26]]},"reference":[{"key":"940_CR1","doi-asserted-by":"crossref","unstructured":"Krammer F, Smith G, Fouchier R, Peiris M, Kedzierska K, Doherty PC, Palese P, Shaw ML, Treanor J, Webster RG, et al. Influenza. NAT Rev Dis Primers. 2018;4(1):3.","DOI":"10.1038\/s41572-018-0002-y"},{"issue":"27","key":"940_CR2","doi-asserted-by":"publisher","first-page":"3960","DOI":"10.1016\/j.vaccine.2018.05.057","volume":"36","author":"W Putri","year":"2018","unstructured":"Putri W, Muscatello DJ, Stockwell MS, Newall AT. Economic burden of seasonal influenza in the united States. Vaccine. 2018;36(27):3960\u20136.","journal-title":"VACCINE"},{"issue":"10353","key":"940_CR3","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1016\/S0140-6736(22)00982-5","volume":"400","author":"TM Uyeki","year":"2022","unstructured":"Uyeki TM, Hui DS, Zambon M, Wentworth DE, Monto AS. Influenza LANCET. 2022;400(10353):693\u2013706.","journal-title":"Influenza LANCET"},{"issue":"6","key":"940_CR4","doi-asserted-by":"publisher","first-page":"1528","DOI":"10.1016\/j.ajpath.2014.08.030","volume":"185","author":"JC Kash","year":"2015","unstructured":"Kash JC, Taubenberger JK. The role of viral, host, and secondary bacterial factors in influenza pathogenesis. Am J Pathol. 2015;185(6):1528\u201336.","journal-title":"AM J PATHOL"},{"issue":"1","key":"940_CR5","doi-asserted-by":"publisher","first-page":"1209","DOI":"10.1186\/s12913-022-08586-y","volume":"22","author":"AM Near","year":"2022","unstructured":"Near AM, Tse J, Young-Xu Y, Hong DK, Reyes CM. Burden of influenza hospitalization among high-risk groups in the united States. BMC Health Serv Res. 2022;22(1):1209.","journal-title":"BMC HEALTH SERV RES"},{"issue":"3","key":"940_CR6","doi-asserted-by":"publisher","first-page":"e1003550","DOI":"10.1371\/journal.pmed.1003550","volume":"18","author":"KE Lafond","year":"2021","unstructured":"Lafond KE, Porter RM, Whaley MJ, Suizan Z, Ran Z, Aleem MA, Thapa B, Sar B, Proschle VS, Peng Z, et al. Global burden of influenza-associated lower respiratory tract infections and hospitalizations among adults: A systematic review and meta-analysis. Plos Med. 2021;18(3):e1003550.","journal-title":"PLOS MED"},{"key":"940_CR7","doi-asserted-by":"crossref","unstructured":"Beigel JH, Hayden FG. Influenza therapeutics in clinical Practice-Challenges and recent advances. Csh Perspect Med. 2021;11(4).","DOI":"10.1101\/cshperspect.a038463"},{"issue":"2","key":"940_CR8","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1080\/17460441.2019.1560261","volume":"14","author":"WJ Shin","year":"2019","unstructured":"Shin WJ, Seong BL. Novel antiviral drug discovery strategies to tackle drug-resistant mutants of influenza virus strains. EXPERT Opin Drug Dis. 2019;14(2):153\u201368.","journal-title":"EXPERT OPIN DRUG DIS"},{"key":"940_CR9","doi-asserted-by":"publisher","first-page":"105499","DOI":"10.1016\/j.antiviral.2022.105499","volume":"210","author":"JC Jones","year":"2023","unstructured":"Jones JC, Yen H, Adams P, Armstrong K, Govorkova EA. Influenza antivirals and their role in pandemic preparedness. Antivir Res. 2023;210:105499.","journal-title":"ANTIVIR RES"},{"issue":"7","key":"940_CR10","doi-asserted-by":"publisher","first-page":"1201","DOI":"10.1007\/s10096-020-03840-9","volume":"39","author":"T Lampejo","year":"2020","unstructured":"Lampejo T. Influenza and antiviral resistance: an overview. Eur J Clin Microbiol. 2020;39(7):1201\u20138.","journal-title":"EUR J CLIN MICROBIOL"},{"key":"940_CR11","doi-asserted-by":"publisher","first-page":"105281","DOI":"10.1016\/j.antiviral.2022.105281","volume":"200","author":"EA Govorkova","year":"2022","unstructured":"Govorkova EA, Takashita E, Daniels RS, Fujisaki S, Presser LD, Patel MC, Huang W, Lackenby A, Nguyen HT, Pereyaslov D, et al. Global update on the susceptibilities of human influenza viruses to neuraminidase inhibitors and the cap-dependent endonuclease inhibitor Baloxavir, 2018\u20132020. Antivir Res. 2022;200:105281.","journal-title":"ANTIVIR RES"},{"key":"940_CR12","doi-asserted-by":"crossref","unstructured":"Shirley M. baloxavir marboxil: A Review in Acute Uncomplicated Influenza. Drugs. 2020, 80(11):1109\u20131118.","DOI":"10.1007\/s40265-020-01350-8"},{"issue":"2","key":"940_CR13","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/j.mjafi.2021.09.005","volume":"78","author":"A Tejus","year":"2022","unstructured":"Tejus A, Mathur AG, Pradhan S, Malik S, Salmani MF. Drug update - baloxavir marboxil: latest entrant into the arena of pharmacotherapy of influenza. Med J Armed Forces India. 2022;78(2):125\u201330.","journal-title":"Med J Armed Forces India"},{"key":"940_CR14","doi-asserted-by":"publisher","first-page":"1581","DOI":"10.3389\/fimmu.2018.01581","volume":"9","author":"D Dou","year":"2018","unstructured":"Dou D, Revol R, Ostbye H, Wang H, Daniels R. Influenza A virus cell entry, replication, virion assembly and movement. Front Immunol. 2018;9:1581.","journal-title":"FRONT IMMUNOL"},{"key":"940_CR15","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.coviro.2019.01.006","volume":"35","author":"R O\u2019Hanlon","year":"2019","unstructured":"O\u2019Hanlon R, Shaw ML. baloxavir marboxil: the new influenza drug on the market. Curr Opin Virol. 2019;35:14\u20138.","journal-title":"CURR OPIN VIROL"},{"key":"940_CR16","doi-asserted-by":"crossref","unstructured":"Dufrasne F. baloxavir marboxil: an original new drug against influenza. Pharmaceuticals-Base. 2021;15(1).","DOI":"10.3390\/ph15010028"},{"issue":"3","key":"940_CR17","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1093\/jamia\/ocv153","volume":"23","author":"TA Kass-Hout","year":"2016","unstructured":"Kass-Hout TA, Xu Z, Mohebbi M, Nelsen H, Baker A, Levine J, Johanson E, Bright RA. OpenFDA: an innovative platform providing access to a wealth of FDA\u2019s publicly available data. J Am Med Inf Assn. 2016;23(3):596\u2013600.","journal-title":"J AM MED Inf ASSN"},{"issue":"8","key":"940_CR18","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1002\/pds.1001","volume":"13","author":"KJ Rothman","year":"2004","unstructured":"Rothman KJ, Lanes S, Sacks ST. The reporting odds ratio and its advantages over the proportional reporting ratio. Pharmacoepidem DR S. 2004;13(8):519\u201323.","journal-title":"PHARMACOEPIDEM DR S"},{"issue":"6","key":"940_CR19","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1002\/pds.677","volume":"10","author":"SJ Evans","year":"2001","unstructured":"Evans SJ, Waller PC, Davis S. Use of proportional reporting ratios (PRRs) for signal generation from spontaneous adverse drug reaction reports. Pharmacoepidem DR S. 2001;10(6):483\u20136.","journal-title":"PHARMACOEPIDEM DR S"},{"issue":"4","key":"940_CR20","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1007\/s002280050466","volume":"54","author":"A Bate","year":"1998","unstructured":"Bate A, Lindquist M, Edwards IR, Olsson S, Orre R, Lansner A, De Freitas RM. A bayesian neural network method for adverse drugreaction signal generation. Eur J Clin Pharmacol. 1998;54(4):315\u201321.","journal-title":"EUR J CLIN PHARMACOL"},{"issue":"6","key":"940_CR21","doi-asserted-by":"publisher","first-page":"533","DOI":"10.2165\/00002018-200023060-00004","volume":"23","author":"M Lindquist","year":"2000","unstructured":"Lindquist M, St Hl M, Bate A, Edwards IR, Meyboom RHB. A retrospective evaluation of a data mining approach to aid finding new adverse drug reaction signals in the WHO international database. Drug Saf. 2000;23(6):533\u201342.","journal-title":"Drug Saf"},{"key":"940_CR22","doi-asserted-by":"publisher","first-page":"116385","DOI":"10.1016\/j.socscimed.2023.116385","volume":"339","author":"KMN Lee","year":"2023","unstructured":"Lee KMN, Rushovich T, Gompers A, Boulicault M, Worthington S, Lockhart JW, Richardson SS. A gender hypothesis of sex disparities in adverse drug events. Soc Sci Med. 2023;339:116385.","journal-title":"SOC SCI MED"},{"issue":"22","key":"940_CR23","doi-asserted-by":"publisher","first-page":"2334","DOI":"10.1001\/jama.2020.21869","volume":"324","author":"TM Uyeki","year":"2020","unstructured":"Uyeki TM. High-risk groups for influenza complications. Jama-J Am Med Assoc. 2020;324(22):2334.","journal-title":"JAMA-J AM MED ASSOC"},{"issue":"10","key":"940_CR24","doi-asserted-by":"publisher","first-page":"961","DOI":"10.1080\/14787210.2016.1227701","volume":"14","author":"N Principi","year":"2016","unstructured":"Principi N, Esposito S. Severe influenza in children: incidence and risk factors. Expert Rev Anti-Infe. 2016;14(10):961\u20138.","journal-title":"EXPERT REV ANTI-INFE"},{"issue":"8","key":"940_CR25","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1097\/INF.0000000000002747","volume":"39","author":"J Baker","year":"2020","unstructured":"Baker J, Block SL, Matharu B, Burleigh ML, Wildum S, Dimonaco S, Collinson N, Clinch B, Piedra PA. baloxavir marboxil Single-dose treatment in Influenza-infected children: A randomized, Double-blind, active controlled phase 3 safety and efficacy trial (miniSTONE-2). Pediatr Infect Dis J. 2020;39(8):700\u20135.","journal-title":"PEDIATR INFECT DIS J"},{"issue":"11","key":"940_CR26","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1097\/INF.0000000000004062","volume":"42","author":"JB Baker","year":"2023","unstructured":"Baker JB, Block SL, Cagas SE, Macutkiewicz LB, Collins C, Sadeghi M, Sarkar S, Williams S. Safety and efficacy of baloxavir marboxil in Influenza-infected children 5\u201311 years of age: A post hoc analysis of a phase 3 study. Pediatr Infect Dis J. 2023;42(11):983\u20139.","journal-title":"PEDIATR INFECT DIS J"},{"issue":"1","key":"940_CR27","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1186\/s12887-023-03841-5","volume":"23","author":"N Hirotsu","year":"2023","unstructured":"Hirotsu N, Sakaguchi H, Fukao K, Kojima S, Piedra PA, Tsuchiya K, Uehara T. Baloxavir safety and clinical and virologic outcomes in influenza virus-infected pediatric patients by age group: age-based pooled analysis of two pediatric studies conducted in Japan. BMC Pediatr. 2023;23(1):35.","journal-title":"BMC PEDIATR"},{"issue":"10","key":"940_CR28","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1056\/NEJMoa1716197","volume":"379","author":"FG Hayden","year":"2018","unstructured":"Hayden FG, Sugaya N, Hirotsu N, Lee N, de Jong MD, Hurt AC, Ishida T, Sekino H, Yamada K, Portsmouth S, et al. baloxavir marboxil for uncomplicated influenza in adults and adolescents. New Engl J Med. 2018;379(10):913\u201323.","journal-title":"NEW ENGL J MED"},{"issue":"10","key":"940_CR29","doi-asserted-by":"publisher","first-page":"1204","DOI":"10.1016\/S1473-3099(20)30004-9","volume":"20","author":"MG Ison","year":"2020","unstructured":"Ison MG, Portsmouth S, Yoshida Y, Shishido T, Mitchener M, Tsuchiya K, Uehara T, Hayden FG. Early treatment with baloxavir marboxil in high-risk adolescent and adult outpatients with uncomplicated influenza (CAPSTONE-2): a randomised, placebo-controlled, phase 3 trial. Lancet Infect Dis. 2020;20(10):1204\u201314.","journal-title":"LANCET INFECT DIS"},{"issue":"7","key":"940_CR30","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1016\/j.jiac.2020.04.014","volume":"26","author":"M Nakazawa","year":"2020","unstructured":"Nakazawa M, Hara K, Komeda T, Ogura E. Safety and effectiveness of baloxavir marboxil for the treatment of influenza in Japanese clinical practice: A postmarketing surveillance of more than 3000 patients. J Infect Chemother. 2020;26(7):729\u201335.","journal-title":"J INFECT CHEMOTHER"},{"issue":"4","key":"940_CR31","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1093\/cid\/ciz908","volume":"71","author":"N Hirotsu","year":"2020","unstructured":"Hirotsu N, Sakaguchi H, Sato C, Ishibashi T, Baba K, Omoto S, Shishido T, Tsuchiya K, Hayden FG, Uehara T, et al. baloxavir marboxil in Japanese pediatric patients with influenza: safety and clinical and virologic outcomes. Clin Infect Dis. 2020;71(4):971\u201381.","journal-title":"CLIN INFECT DIS"},{"issue":"1","key":"940_CR32","doi-asserted-by":"publisher","first-page":"9633","DOI":"10.1038\/s41598-018-27890-4","volume":"8","author":"S Omoto","year":"2018","unstructured":"Omoto S, Speranzini V, Hashimoto T, Noshi T, Yamaguchi H, Kawai M, Kawaguchi K, Uehara T, Shishido T, Naito A, et al. Characterization of influenza virus variants induced by treatment with the endonuclease inhibitor baloxavir marboxil. Sci Rep-UK. 2018;8(1):9633.","journal-title":"SCI REP-UK"},{"issue":"8","key":"940_CR33","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1097\/INF.0000000000002748","volume":"39","author":"T Yokoyama","year":"2020","unstructured":"Yokoyama T, Sakaguchi H, Ishibashi T, Shishido T, Piedra PA, Sato C, Tsuchiya K, Uehara T. baloxavir marboxil 2% granules in Japanese children with influenza: an Open-label phase 3 study. Pediatr Infect Dis J. 2020;39(8):706\u201312.","journal-title":"PEDIATR INFECT DIS J"},{"issue":"12","key":"940_CR34","doi-asserted-by":"publisher","first-page":"1040","DOI":"10.1016\/j.jiac.2019.05.009","volume":"25","author":"N Kanai","year":"2019","unstructured":"Kanai N, Hashimoto T, Fukuda M, Shijyo T. Acute ischemic colitis with hematochezia related to baloxavir marboxil treatment for influenza A. J Infect Chemother. 2019;25(12):1040\u20132.","journal-title":"J INFECT CHEMOTHER"},{"key":"940_CR35","doi-asserted-by":"publisher","first-page":"37","DOI":"10.18433\/jpps31375","volume":"24","author":"K Kurosawa","year":"2021","unstructured":"Kurosawa K, Takasaki S, Suzuki H, Sato Y, Akiyama M, Akiba M, Saiki Y, Mano N. A case of an increase in prothrombin Time-International normalized ratio by interaction between warfarin and baloxavir marboxil in a patient on implantable ventricular assist device. J Pharm Pharm Sci. 2021;24:37\u201340.","journal-title":"J Pharm Pharm Sci"},{"issue":"4","key":"940_CR36","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1038\/cmi.2016.1","volume":"13","author":"Y Yang","year":"2016","unstructured":"Yang Y, Tang H. Aberrant coagulation causes a hyper-inflammatory response in severe influenza pneumonia. Cell Mol Immunol.2016;13(4):432\u201342.","journal-title":"CELL MOL IMMUNOL"},{"issue":"11","key":"940_CR37","doi-asserted-by":"publisher","first-page":"2009","DOI":"10.1007\/s00467-017-3783-4","volume":"33","author":"M Bitzan","year":"2018","unstructured":"Bitzan M, Zieg J. Influenza-associated thrombotic microangiopathies. Pediatr Nephrol. 2018;33(11):2009\u201325.","journal-title":"PEDIATR NEPHROL"},{"issue":"6","key":"940_CR38","first-page":"480","volume":"44","author":"S Okayama","year":"2011","unstructured":"Okayama S, Arakawa S, Ogawa K, Makino T. A case of hemorrhagic colitis after influenza A infection. J Microbiol Immunol. 2011;44(6):480\u20133.","journal-title":"J MICROBIOL IMMUNOL"},{"issue":"6","key":"940_CR39","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1002\/pds.5392","volume":"31","author":"A Hara","year":"2022","unstructured":"Hara A, Hara K, Komeda T, Ogura E, Miyazawa S, Kobayashi C, Fujiwara M, Yoshida M, Urushihara H. Comparison of the incidence of bleeding between baloxavir marboxil and other anti-influenza drugs among outpatients with influenza virus infection: A retrospective cohort study using an employment-based health insurance claims database in Japan. Pharmacoepidem DR S. 2022;31(6):623\u201331.","journal-title":"PHARMACOEPIDEM DR S"},{"issue":"6","key":"940_CR40","doi-asserted-by":"publisher","first-page":"1318","DOI":"10.1016\/j.jaci.2014.08.018","volume":"134","author":"E Jerschow","year":"2014","unstructured":"Jerschow E, Lin RY, Scaperotti MM, McGinn AP. Fatal anaphylaxis in the united States, 1999\u20132010: Temporal patterns and demographic associations. J Allergy Clin Immun. 2014;134(6):1318\u201328.","journal-title":"J ALLERGY CLIN IMMUN"},{"issue":"3","key":"940_CR41","doi-asserted-by":"publisher","first-page":"150","DOI":"10.5582\/ddt.2021.01053","volume":"15","author":"H Tanaka","year":"2021","unstructured":"Tanaka H, Ohyama K, Horikomi Y, Ishii T. Association between anaphylaxis and anti-influenza drug use: an analysis of the Japanese adverse drug event report database. Drug Discoveries Ther. 2021;15(3):150\u20135.","journal-title":"Drug Discoveries Ther"},{"issue":"12","key":"940_CR42","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.1007\/s40261-018-0710-9","volume":"38","author":"H Koshimichi","year":"2018","unstructured":"Koshimichi H, Ishibashi T, Kawaguchi N, Sato C, Kawasaki A, Wajima T. Safety, tolerability, and pharmacokinetics of the novel Anti-influenza agent baloxavir marboxil in healthy adults: phase I study findings. Clin Drug Invest. 2018;38(12):1189\u201396.","journal-title":"CLIN DRUG INVEST"},{"issue":"9","key":"940_CR43","doi-asserted-by":"publisher","first-page":"3112","DOI":"10.1016\/j.xphs.2019.04.010","volume":"108","author":"H Koshimichi","year":"2019","unstructured":"Koshimichi H, Ishibashi T, Wajima T. Population pharmacokinetics of baloxavir marboxil in Japanese pediatric influenza patients. J Pharm Sci-US. 2019;108(9):3112\u20137.","journal-title":"J PHARM SCI-US"},{"issue":"2","key":"940_CR44","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1111\/cts.13160","volume":"15","author":"Y Kim","year":"2022","unstructured":"Kim Y, Lee S, Kim Y, Jang IJ, Lee S. Pharmacokinetics and safety of a novel influenza treatment (baloxavir marboxil) in Korean subjects compared with Japanese subjects. CTS-Clin Transl Sci. 2022;15(2):422\u201332.","journal-title":"CTS-CLIN TRANSL SCI"},{"issue":"5","key":"940_CR45","doi-asserted-by":"publisher","first-page":"1196","DOI":"10.1111\/cts.13237","volume":"15","author":"Y Liu","year":"2022","unstructured":"Liu Y, Retout S, Duval V, Jia J, Zou Y, Wang Y, Cosson V, Jolivet S, De Buck S. Pharmacokinetics, safety, and simulated efficacy of an influenza treatment, baloxavir marboxil, in Chinese individuals. CTS-Clin Transl Sci. 2022;15(5):1196\u2013203.","journal-title":"CTS-CLIN TRANSL SCI"},{"issue":"3","key":"940_CR46","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1007\/s004670050299","volume":"11","author":"KM Dell","year":"1997","unstructured":"Dell KM, Schulman SL. Rhabdomyolysis and acute renal failure in a child with influenza A infection. Pediatr Nephrol. 1997;11(3):363\u20135.","journal-title":"PEDIATR NEPHROL"},{"issue":"7","key":"940_CR47","doi-asserted-by":"publisher","first-page":"680","DOI":"10.1056\/NEJMoa0904252","volume":"361","author":"R Perez-Padilla","year":"2009","unstructured":"Perez-Padilla R, de la Rosa-Zamboni D, Ponce DLS, Hernandez M, Quinones-Falconi F, Bautista E, Ramirez-Venegas A, Rojas-Serrano J, Ormsby CE, Corrales A, et al. Pneumonia and respiratory failure from swine-origin influenza A (H1N1) in Mexico. New Engl J Med. 2009;361(7):680\u20139.","journal-title":"NEW ENGL J MED"},{"issue":"4","key":"940_CR48","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1111\/j.1469-0691.2010.03185.x","volume":"16","author":"M Parikh","year":"2010","unstructured":"Parikh M, Dolson G, Ramanathan V, Sangsiraprapha W. Novel H1N1-associated rhabdomyolysis leading to acute renal failure. Clin Microbiol Infec. 2010;16(4):330\u20132.","journal-title":"CLIN MICROBIOL INFEC"},{"issue":"2","key":"940_CR49","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1111\/j.1744-9987.2010.00900.x","volume":"15","author":"E Sato","year":"2011","unstructured":"Sato E, Nakamura T, Koide H. Rhabdomyolysis induced by influenza A infection: case report and review of literature. Ther ApherDial. 2011;15(2):208\u20139.","journal-title":"THER APHER DIAL"},{"issue":"3","key":"940_CR50","doi-asserted-by":"publisher","first-page":"122","DOI":"10.4103\/1947-2714.153926","volume":"7","author":"MF Fadila","year":"2015","unstructured":"Fadila MF, Wool KJ. Rhabdomyolysis secondary to influenza A infection: a case report and review of the literature. N Am J Med Sci. 2015;7(3):122\u20134.","journal-title":"N Am J Med Sci"}],"container-title":["BMC Pharmacology and Toxicology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40360-025-00940-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40360-025-00940-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40360-025-00940-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,26]],"date-time":"2025-05-26T18:02:34Z","timestamp":1748282554000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcpharmacoltoxicol.biomedcentral.com\/articles\/10.1186\/s40360-025-00940-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,26]]},"references-count":50,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["940"],"URL":"https:\/\/doi.org\/10.1186\/s40360-025-00940-0","relation":{},"ISSN":["2050-6511"],"issn-type":[{"value":"2050-6511","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,26]]},"assertion":[{"value":"24 April 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 May 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 May 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable. This study was deemed non-human subject related research.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"110"}}